Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Osteolysis and cancer.

× No keyword cloud information.

20 in total

Review 1. Osteoprotegerin ligand: a regulator of immune responses and bone physiology.

Authors: Y Y Kong; W J Boyle; J M Penninger
Journal: Immunol Today Date: 2000-10

2. Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro.

Authors: N Chikatsu; Y Takeuchi; Y Tamura; S Fukumoto; K Yano; E Tsuda; E Ogata; T Fujita
Journal: Biochem Biophys Res Commun Date: 2000-01-19 Impact factor: 3.575

3. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy.

Authors: C Capparelli; P J Kostenuik; S Morony; C Starnes; B Weimann; G Van; S Scully; M Qi; D L Lacey; C R Dunstan
Journal: Cancer Res Date: 2000-02-15 Impact factor: 12.701

4. Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation.

Authors: M Nagai; S Kyakumoto; N Sato
Journal: Biochem Biophys Res Commun Date: 2000-03-16 Impact factor: 3.575

5. Breast cancer cells interact with osteoblasts to support osteoclast formation.

Authors: R J Thomas; T A Guise; J J Yin; J Elliott; N J Horwood; T J Martin; M T Gillespie
Journal: Endocrinology Date: 1999-10 Impact factor: 4.736

Review 6. Molecular basis of the spectrum of skeletal complications of neoplasia.

Authors: D Goltzman; A C Karaplis; R Kremer; S A Rabbani
Journal: Cancer Date: 2000-06-15 Impact factor: 6.860

Review 7. Cellular and molecular mechanisms of action of bisphosphonates.

Authors: M J Rogers; S Gordon; H L Benford; F P Coxon; S P Luckman; J Monkkonen; J C Frith
Journal: Cancer Date: 2000-06-15 Impact factor: 6.860

Review 8. Molecular mechanisms of osteolytic bone metastases.

Authors: T A Guise
Journal: Cancer Date: 2000-06-15 Impact factor: 6.860

Review 9. Molecular mechanisms of tumor-bone interactions in osteolytic metastases.

Authors: J M Chirgwin; T A Guise
Journal: Crit Rev Eukaryot Gene Expr Date: 2000 Impact factor: 1.807

10. Bisphosphonates induce apoptosis in human breast cancer cell lines.

Authors: S G Senaratne; G Pirianov; J L Mansi; T R Arnett; K W Colston
Journal: Br J Cancer Date: 2000-04 Impact factor: 7.640

18 in total

1. Immunohistochemical analysis of low-grade and high-grade prostate carcinoma: relative changes of parathyroid hormone-related protein and its parathyroid hormone 1 receptor, osteoprotegerin and receptor activator of nuclear factor-kB ligand.

Authors: Francisco C Pérez-Martínez; Verónica Alonso; José L Sarasa; Syon-Ghyun Nam-Cha; Remigio Vela-Navarrete; Félix Manzarbeitia; Francisco J Calahorra; Pedro Esbrit
Journal: J Clin Pathol Date: 2006-06-14 Impact factor: 3.411

2. Transforming growth factor-{beta} coordinately induces suppressor of cytokine signaling 3 and leukemia inhibitory factor to suppress osteoclast apoptosis.

Authors: Ming Ruan; Larry Pederson; Elizabeth W Bradley; Ana-Maria Bamberger; Merry Jo Oursler
Journal: Endocrinology Date: 2010-02-24 Impact factor: 4.736

3. RANK, RANKL and OPG Expression in Breast Cancer - Influence on Osseous Metastasis.

Authors: J T Ney; T Fehm; I Juhasz-Boess; E F Solomayer
Journal: Geburtshilfe Frauenheilkd Date: 2012-05 Impact factor: 2.915

4. Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma.

Authors: Vasilios Liapis; Agatha Labrinidis; Irene Zinonos; Shelley Hay; Vladimir Ponomarev; Vasilios Panagopoulos; Mark DeNichilo; Wendy Ingman; Gerald J Atkins; David M Findlay; Andrew C W Zannettino; Andreas Evdokiou
Journal: Cancer Lett Date: 2014-11-15 Impact factor: 8.679

5. Bone-invasive oral squamous cell carcinoma in cats: pathology and expression of parathyroid hormone-related protein.

Authors: C K Martin; S H Tannehill-Gregg; T D Wolfe; T J Rosol
Journal: Vet Pathol Date: 2010-10-12 Impact factor: 2.221

6. Regulation of gene expression and inhibition of experimental prostate cancer bone metastasis by dietary genistein.

Authors: Yiwei Li; Mingxin Che; Sunita Bhagat; Kerrie-Lynn Ellis; Omer Kucuk; Daniel R Doerge; Judith Abrams; Michael L Cher; Fazlul H Sarkar
Journal: Neoplasia Date: 2004 Jul-Aug Impact factor: 5.715

Review 7. RANKL/RANK/OPG: key therapeutic target in bone oncology.

Authors: Kosei Ando; Kanji Mori; Francoise Rédini; Dominique Heymann
Journal: Curr Drug Discov Technol Date: 2008-09

8. Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model.

Authors: Agatha Labrinidis; Shelley Hay; Vasilios Liapis; Vladimir Ponomarev; David M Findlay; Andreas Evdokiou
Journal: Clin Cancer Res Date: 2009-04-28 Impact factor: 12.531

9. Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.

Authors: Eva Grimaud; Luc Soubigou; Séverine Couillaud; Patrick Coipeau; Anne Moreau; Norbert Passuti; François Gouin; Françoise Redini; Dominique Heymann
Journal: Am J Pathol Date: 2003-11 Impact factor: 4.307

10. A tale of mice and (wo)men: development of and insights from an "all human" animal model of breast cancer metastasis to bone.

Authors: Michael Rosenblatt
Journal: Trans Am Clin Climatol Assoc Date: 2012